Clinical Trials
7 trialsNCT03126591 2024-10-23
A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma
Eli Lilly and Company
Phase 1 Completed
NCT03985722 2023-03-27
OLATRASTS
Grupo Espanol de Investigacion en Sarcomas
Phase 1 Unknown
NCT03056599 2021-09-24
Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma
Presage Biosciences
Phase 1 Completed
NCT03283696 2020-09-10
A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma
Eli Lilly and Company
Phase 1 Completed
NCT02326025 2019-11-21
A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma
Eli Lilly and Company
Phase 1 Completed
NCT02783599 2019-08-12
A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma
Eli Lilly and Company
Phase 1 Completed
NCT03437070 2019-03-18
Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma
University of Miami
Phase 1 Withdrawn